Bayer wins U.S. patent dispute, USPTO rules Pharmacyclics patent invalid.

On the morning of April 30, BeiGene announced that on June 13, 2023, Pharmacyclics LLC filed a lawsuit in the Delaware Court against the company and its wholly-owned subsidiary BeOne Medicines USA, Inc., claiming that the company's product BeiYueZe infringed on its US Patent No. 11,672,803 authorized on June 13, 2023, and requested the court to determine that the company and BeOne Medicines USA, Inc. engaged in activities related to BeiYueZe that have caused or will cause others to infringe on its patent, and to provide appropriate compensation and other remedies as the court deems appropriate. On April 29, 2025, the US Patent and Trademark Office made a final written decision declaring that the entire rights of the '803 patent challenged by the company in the post-authorization review process of the '803 patent were invalid. Pharmacyclics may appeal the USPTO's final written decision. BeiYueZe is the company's original drug, and the company will vigorously defend against such patent infringement allegations.